Literature DB >> 287038

Chemotactic factor for tumor cells derived from the C5a fragment of complement component C5.

W Orr, S H Phan, J Varani, P A Ward, D L Kreutzer, R O Webster, P M Henson.   

Abstract

Previously, we have stablished that the fifth component of complement (C5) serves as an important source of mediators that have locomotory (chemotactic) activity for leukocytes and tumor cells. C5a, a fragment (Mr 11,200) derived from the NH2-terminal portion of the alpha chain of C5, is the major chemotactic peptide for leukocytes. The present studies demonstrate that cleavage of C5a with trypsin generates a derivative peptide that is chemotactic for tumor cells (Walker carcinosarcoma). This fragment has an estimated Mr of 6000 as assessed by gel filtration and does not require the COOH-terminal arginine of C5a, because equivalent amounts of chemotactic activity for tumor cells can be generated from des-Arg-C5a by digestion with trypsin. The C5a-derived chemotactic peptide for tumor cells demonstrates peak activity at approximately 1 pM. These studies emphasize the key role of the C5a region of the C5 molecule in the generation of peptides that affect locomotory responses of cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 287038      PMCID: PMC383518          DOI: 10.1073/pnas.76.4.1986

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

Review 2.  Biology of leukotaxis.

Authors:  P A Ward; E L Becker
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

3.  Resorbing bone is chemotactic for monocytes.

Authors:  G R Mundy; J Varani; W Orr; M D Gondek; P A Ward
Journal:  Nature       Date:  1978-09-14       Impact factor: 49.962

4.  Relationship between the C5 peptides chemotactic for leukocytes and tumor cells.

Authors:  A G Romualdez; P A Ward; T Torikata
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

5.  Raipid stimulation of protein carboxymethylation in leukocytes by a chemotatic peptide.

Authors:  R F O'Dea; O H Viveros; J Axelrod; S Aswanikaumar; E Schiffmann; B A Corcoran
Journal:  Nature       Date:  1978-03-30       Impact factor: 49.962

6.  The evidence for the existence of chymotrypsin-like esterase activity in the plasma membranes of rabbit neutrophils and the specific chemotactic peptide binding activity of the subcellular fractions.

Authors:  P K Tsung; S W Kegeles; E L Becker
Journal:  Biochim Biophys Acta       Date:  1978-06-15

7.  Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

8.  Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes.

Authors:  D E Chenoweth; T E Hugli
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

9.  Characteristics of the chemotactic response of neoplastic cells to a factor derived from the fifth component of complement.

Authors:  W Orr; J Varani; P A Ward
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

10.  Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes.

Authors:  L T Williams; R Snyderman; M C Pike; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

View more
  10 in total

Review 1.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

Review 2.  Tumor invasion and host extracellular matrix.

Authors:  B U Pauli; D E Schwartz; E J Thonar; K E Kuettner
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  Partial characterization of a bone-derived chemotactic factor for tumor cells.

Authors:  F W Orr; J Varani; M D Gondek; P A Ward; G R Mundy
Journal:  Am J Pathol       Date:  1980-04       Impact factor: 4.307

4.  Growth and metastasis of hypermotile, hyperinvasive cancer cells selected in vitro by rapid locomotion under various conditions.

Authors:  I A Grimstad
Journal:  Clin Exp Metastasis       Date:  1988 Jul-Aug       Impact factor: 5.150

5.  The chemotactic response of tumor cells. A model for cancer metastasis.

Authors:  W C Lam; E J Delikatny; F W Orr; J Wass; J Varani; P A Ward
Journal:  Am J Pathol       Date:  1981-07       Impact factor: 4.307

6.  Isolation of three separate anaphylatoxins from complement-activated human serum.

Authors:  T E Hugli; C Gerard; M Kawahara; M E Scheetz; R Barton; S Briggs; G Koppel; S Russell
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

7.  Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells.

Authors:  F W Orr; S Mokashi; J Delikatny
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

8.  Detection of a complement-derived chemotactic factor for tumor cells in human inflammatory and neoplastic effusions.

Authors:  F W Orr; E J Delikatny; S Mokashi; G V Krepart; H G Stiver
Journal:  Am J Pathol       Date:  1983-01       Impact factor: 4.307

9.  Comparison of the chemotactic responsiveness of two fibrosarcoma subpopulations of differing malignancy.

Authors:  F W Orr; J Varani; J Delikatny; N Jain; P A Ward
Journal:  Am J Pathol       Date:  1981-02       Impact factor: 4.307

10.  Chemotaxis of metastatic tumor cells.

Authors:  J Varani
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.